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OBJECTIVES Ventricular resynchronization might be achieved in a minimally invasive fashion using a
robotically assisted, direct left ventricular (LV) epicardial approach.
BACKGROUND Approximately 10% of patients undergoing biventricular pacemaker insertion have a failure of
coronary sinus (CS) cannulation. Rescue therapy for these patients currently is limited to
standard open surgical techniques.
METHODS Ten patients with congestive heart failure (New York Heart Association class 3.4  0.5) and
a widened QRS complex (184 31 ms) underwent robotic LV lead placement after failed CS
cannulation. Mean patient age was 71  12 years, LV ejection fraction (EF) was 12  6%,
and LV end-diastolic diameter was 7.1 1.3 cm. Three patients had previous cardiac surgery,
and five patients had a prior device implanted.
RESULTS Nineteen epicardial leads were successfully placed on the posterobasal surface of the LV.
Intraoperative lead threshold was 1.0  0.5 V at 0.5 ms, R-wave was 18.6  8.6 mV, and
impedance was 1,143  261 ohms at 0.5 V. Complications included an intraoperative LV
injury and a postoperative pneumonia. Improvements in exercise tolerance (8 of 10 patients),
EF (19  13%, p  0.04), and QRS duration (152  21 ms, p  0.006) have been noted
at three to six months follow-up. Lead thresholds have remained unchanged (2.1  1.4 V at
0.5 ms, p  NS), and a significant drop in impedance (310  59 ohms, p  0.001) has been
measured.
CONCLUSIONS Robotic LV lead placement is an effective and novel technique which can be used for
ventricular resynchronization therapy in patients with no other minimally invasive options for
biventricular pacing. (J Am Coll Cardiol 2003;41:1414–9) © 2003 by the American
College of Cardiology Foundation
Approximately 30% of patients with heart failure exhibit
significant ventricular dysynchrony secondary to alterations
in intraventricular conduction as manifested by a widened
QRS complex on 12-lead electrocardiogram (1). This ven-
tricular dysynchrony further impairs the already depressed
cardiac contractility of patients with both idiopathic and
ischemic cardiomyopathies. The altered contraction pattern
may worsen mitral regurgitation and is associated with an
increased risk of death (2–4).
Prospective randomized trials have demonstrated im-
provements in ventricular function, exercise capacity, and
quality of life among patients undergoing ventricular resyn-
chronization therapy via biventricular pacing (5–8). How-
ever, technical limitations owing to individual coronary
sinus (CS) and coronary venous anatomy result in a 10% to
15% failure rate of left ventricular (LV) lead placement and
effective biventricular pacing (7,8). Lead dislodgement con-
tributes to an additional 5% to 10% late failure rate of LV
lead capture (9). Rescue therapy for these frail patients has
typically involved LV epicardial lead placement through a
limited anterior thoracotomy.
To provide a minimally invasive option for these patients
with LV lead failures, we began a program of endoscopic,
epicardial LV lead placement with the use of the da Vinci
Robotic Surgical System (Intuitive Surgical Inc., Sunnyvale,
California). We report the intermediate results of roboti-
cally assisted epicardial lead placement for biventricular
pacing in a cohort of patients with previous failure of CS
cannulation.
METHODS
Patients. Ten patients were referred to the surgical ar-
rhythmia service for robotic LV lead implantation after
initial percutaneous attempts at biventricular lead insertion.
The reasons for referral are listed in Table 1. Patient age was
70.5  13 years (range 49 to 87 years), and 80% were male.
The etiology of heart failure was idiopathic in six patients
and ischemic in the other four patients. Preoperative New
York Heart Association (NYHA) heart failure class was 3.4
 0.5, and patients had heart failure symptoms for a mean
of 5.1  2.0 years. Sixty percent were in the hospital with a
heart failure exacerbation, and 40% were electively admitted
to the hospital as outpatients. Three patients had a previous
cardiac procedure: one patient had a pericardiostomy tube
for ventricular perforation six months earlier during inser-
tion of an implantable cardioverter-defibrillator (ICD), and
two patients had previous coronary artery bypass grafting (2
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and 20 years previously). Seven patients had a pre-existing
right-sided pacemaker or ICD in place upon referral.
Preoperative assessment. Written, informed consent was
obtained from all patients as part of an approved Institu-
tional Review Board protocol. Preoperative evaluation con-
sisted of a 12-lead electrocardiogram to document a QRS
complex 130 ms. Dobutamine stress echocardiography
was routinely performed to identify areas of viability and
recruitability as appropriate targets for LV epicardial lead
placement.
Preoperative QRS duration was 184  30 ms (range 136
to 244 ms). Left ventricular ejection fraction (EF) was 12 
6% (range 5% to 25%), LV end-diastolic diameter was 7.1
 1.3 cm (range 5.9 to 9.6 cm), and LV end-systolic
diameter was 6.4  1.7 cm (range 4.3 to 9.2 cm). All
patients demonstrated viability and recruitable myocardial
contractility in the posterolateral and posterobasal segments.
Robotic system. The da Vinci Robotic Surgical System
(Intuitive Surgical Inc., Sunnyvale, California) was used in
all cases. The device is composed of the surgeon control
console and the surgical arm unit that positions and directs
the micro-instruments (Fig. 1A). Unlike standard thoraco-
scopic instruments, these specialized “EndoWrist” instru-
ments have a full seven degrees of freedom, simulating the
motion of a human wrist at the operative site (Fig. 1B).
Insertion of the instruments into the chest cavity is per-
formed through two 8-mm ports. A third 10-mm port is
used to insert the endoscope. The instruments are con-
trolled by a surgeon who sits at the operating console away
from the operative field. Computer interfacing allows for
scaled motion, eliminating tremor and providing for incred-
ibly accurate surgical precision through these small ports.
The surgeon views the surgery through the eyepiece in the
surgical console, which provides high-definition, magnified,
real three-dimensional vision.
Operative technique. All operations were performed un-
der general anesthesia with selective right lung ventilation.
Transesophageal echocardiography was performed rou-
tinely, and Swan-Ganz catheter placement was performed
selectively in accordance with institutional review board-
approved research protocols.
Patients were positioned in the full posterolateral thora-
cotomy position. The da Vinci Robotic Surgical System was
used for all portions of the operation. A camera port was
placed in the seventh intercostal space in the posterior
axillary line. The left and right arms were positioned in the
ninth and fifth intercostal space, respectively (Fig. 2). The
left chest was insufflated at a pressure of 8 to 10 mm Hg. A
10-mm working port was inserted posterior to the camera
port and was used for the introduction of the lead and
sutures as necessary. The pericardium was then opened
posterior to the phrenic nerve, and the first and second
obtuse marginal (OM) vessels were identified (Fig. 3). The
pericardium was retracted with one- or two-stay sutures
which were brought out of the working port. A temporary
pacing wire was used to map the ventricular electrogram and
determine the area of latest activation along the posterobasal
ventricular surface in relation to the patient’s intrinsic QRS
complex. This universally was found to be in the region of
the second OM and third OM vessels. The optimal distance
from base and apex did show some variability.
A pacing lead was then introduced into the chest through
the working port. The robotic arms were used to fix the lead
to the LV surface either by screw in fixation or suture
technique depending on the lead used. The lead was tested
for threshold, resistance, and lateness within the native QRS
complex. This lead was capped and delivered into the chest.
A second lead was then delivered through the working port
and was again fixed to the LV surface near the second OM.
The second lead was occasionally placed as a screw-in lead
by the table surgeon. The pericardium was closed over the
leads in all cases with several silk sutures to aid in permanent
lead fixation.
The first lead was then retrieved from the chest through
the right arm port. Both leads were then tunneled to a
counter incision in the axilla. A chest tube was placed
through the left arm port for evacuation of air and was
removed before leaving the operating room. The port sites
were closed and the patient was repositioned in the supine
position. The patient was reprepared and redraped. If a
prior device had been implanted the pocket was reopened.
Both LV leads were retrieved into the pocket and retested
for threshold. The LV lead with the best threshold was used
as the pacing lead and was connected to the device. The
second lead was secured to the fascia and was left capped in
the pocket as a backup lead for future use if necessary. If a
right-sided pacing or defibrillating lead was required, it was
inserted at this time and the leads were connected to either
a biventricular pacing generator or an ICD/biventricular
pacing device.
Abbreviations and Acronyms
CS  coronary sinus
EF  ejection fraction
ICD  implantable cardioverter defibrillator
LV  left ventricle/ventricular
NYHA  New York Heart Association
OM  obtuse marginal
Table 1. Indications for Robotically Assisted LV Lead
Transplantation
Reason for Referral for Robotic
LV Lead Implantation Number
Occluded coronary sinus 5
Atretic venous tributaries 3
Prior right ventricular perforation 1
Primary implant 1
LV  left ventricular.
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Twelve-lead electocardiograms were obtained in the op-
erating room during right ventricular, LV, and biventricular
pacing. All patients were extubated in the operating room
and observed in the intensive care unit overnight.
All patients had follow-up at three- and six-month
intervals for device interrogation. Interval transthoracic echo-
cardiograms were performed at three and six months and were
assessed for ejection fraction and ventricular volumes.
Statistical analysis. Changes in preoperative and postop-
erative measurements were compared among individual
patients with a paired, two-tailed Student t test.
RESULTS
Nineteen epicardial leads were placed in the 10 patients (one
patient received only one lead). Of the active leads, two were
epicardial steroid eluting sew-on leads (Medtronic CapSure
Epi 4968, 53 cm, Minneapolis, Minnesota) and eight were
screw-in leads (Medtronic Sutureless, Unipolar, Myocardial
Screw-in, 5069, 53 cm). Mean robotic operative time (time
from initial skin incision to patient repositioning) for all
cases was 83  53 min (range 30 to 180 min). A clear
reduction in robotic operative times was detected when the
first five cases (108  54 min) were compared with the last
Figure 1. (A) Photograph of the daVinci Robotic Surgical System showing the surgical arm unit on the left and the surgeon control console on the right.
(B) This image demonstrates the EndoWrist instrument capabilities. Each instrument has seven ranges of motion approximating the movement of a human wrist.
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five cases (50  16 min) (p  0.05) (Fig. 4). All patients
had successful LV lead placement.
There was one intraoperative ventricular injury immedi-
ately after lead placement early in our experience. This was
the result of inadvertent left arm injury to the LV free wall.
Because there is a limited working space in some of these
patients, down lung ventilation can cause significant medi-
astinal shift allowing the LV to move towards the chest wall.
This injury was repaired after extending the right arm port
2 cm. Two pledgeted sutures were placed under both direct
and videoscopic assistance. After this injury, we adopted a
policy of routinely holding ventilation during lead place-
ment. No patient required a blood transfusion and there
were no reoperations for bleeding. One patient developed a
left lower lobe pneumonia three days after robotic lead
placement. This patient had been hospitalized for one
week with a congestive heart failure exacerbation before
surgery.
All patients are alive and well at a mean follow-up of 25
 10 weeks. Eight of ten patients were symptomatically
improved at three months follow-up. As a group, NYHA
class and LV EF were improved at three months (Table 2).
Operative threshold and impedance data are shown in Table
2 and are compared with three-month follow-up lead data.
A statistically significant improvement in QRS duration and
impedance was found at three months follow-up with no
change in lead threshold.
Figure 2. Port placement for totally endoscopic, robotic left ventricular
epicardial lead placement. The ports are placed in line with the tip of the
scapula allowing for posterior access to the left ventricular surface.
Figure 3. Operative photograph of robotic left ventricular lead placement. The pericardium is divided posterior to the phrenic nerve exposing the obtuse
marginal (OM) vessels on the posterolateral wall of the left ventricle. A two-turn, helical screw-in lead is being placed by the console surgeon.
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DISCUSSION
The success of ventricular resynchronization therapy relies
heavily upon proper LV lead placement. Previous studies
have demonstrated that pacing the posterobasal wall of the
LV provides more effective hemodynamic augmentation
than either lateral or anterior positioned leads (10,11).
Despite successful CS cannulation in 85% of percutaneous
LV lead insertions, a much smaller percentage of these
patients actually receive leads positioned in the posterolat-
eral vertical vein of the CS. Long operative and fluoroscopy
times have likewise made percutaneous CS LV lead place-
ment a challenging and meticulous procedure.
Direct access to the LV surface has been described
previously as a rescue procedure in patients with failed CS
leads. These procedures have included both limited thora-
cotomy and thoracoscopic techniques. All of these proce-
dures, however, have targeted the anterior and lateral LV
wall for LV lead placement and have included limited access
to the entire LV surface. The presently described technique
of posterolateral thoracotomy position has several advan-
tages. Access to the most posterior and basal portion of the
LV is possible as far back as the distal circumflex. Likewise,
more lateral and anterolateral regions of the LV can be
easily targeted should preoperative studies or intraoperative
mapping suggest a more beneficial lead site. The postero-
basal surface of the LV is also an area of the LV with a bare
myocardial surface, devoid of epicardial fat, allowing for
excellent lead thresholds. Furthermore, we believe that the
posterior approach is critical for reoperative surgery, as the
posterior pericardial well is frequently least involved in the
adhesive process.
Application of robotic technology to this operation allows
for high-resolution, three-dimensional vision of the ventric-
ular surface. The fine scaling of motion makes opening the
pericardium in these very large hearts quite simple. Suturing
and accurate lead placement are also significantly enhanced
with robotic technology. Despite insufflation, there is fre-
quently little working space and the posterior approach
ensures a reliable entry into the chest. Nonetheless, working
area remains limited in certain cases and the small articu-
lating robotic instruments can become invaluable. A similar
posterior approach might be devised thoracoscopically;
however, a camera fixation device is critical. Nonetheless,
we believe that application of robotics makes this newly
described procedure more accurate, expeditious, and facile
when compared with other currently described surgical
approaches to epicardial lead placement.
Although the patients in the series described herein all
had failed previous percutaneous attempts at epicardial LV
lead placement, the presently described procedure can be
applied as an initial, primary procedure. Potential advan-
tages might exist when compared with percutaneous ap-
proaches. Access to the entire heart gives the surgeon the
ability to place the LV lead in the most hemodynamically
and electrophysiologically advantageous position based on
both preoperative and intraoperative studies. The reproduc-
ibility of the procedure allows it to be done with a near
100% immediate success rate in a very expeditious manner.
The early functional and hemodynamic improvements dem-
onstrated in this study compare favorably with those re-
Figure 4. Bar graph demonstrating the operative time associated with robotic left ventricular epicardial lead placement. A statistically significant difference
in operative time is demonstrated when early and later experiences are compared.
Table 2. Comparison of Electrophysiologic and Hemodynamic
Variables at Baseline and 3 to 6 Months Follow-Up
Baseline
3–6 Months
Postoperative p Value
LVEF (%) 12  6 19  13 0.04
LVEDD (cm) 7.1  1.3 7.2  1.0 NS
LVESD (cm) 6.4  1.7 6.3  1.4 NS
NYHA class 3.4  0.5 1.9  1.0  0.001
QRS duration (ms) 184  31 152  21 0.006
Impedance (volts at 0.5 ms) 1,143  261 310  59  0.001
Threshold (ohms at 5.0 V) 1.0  0.5 2.1  1.4 NS
LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection
fraction; LVESD  left ventricular end-systolic diameter; NYHA  New York
Heart Association.
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ported for percutaneous LV lead placement. A larger
randomized study will be necessary to determine if robotic
LV epicardial lead implantation results in improved func-
tional outcome when compared with CS LV lead place-
ment.
Robotic LV lead placement does have the disadvantage of
requiring general anesthesia and selective single-lung ven-
tilation. Surprisingly, we have found no significant hemo-
dynamic consequences to single-lung ventilation or chest
cavity insufflation in these frail patients with severe cardio-
megaly. We hypothesize that the high intraventricular and
intra-atrial pressures of these hearts may be less susceptible
to extracavitary insufflation than cardiac chambers that are
more compressible. Likewise, the posterior positioning may
serve to allow displacement into the right chest, further
ameliorating the effects of insufflation. Ongoing studies at
our institution hope to delineate the consequences of chest
insufflation and single-lung ventilation in this patient pop-
ulation.
Despite requiring general anesthesia, intraoperative he-
modynamic control of these patients is improved with the
use of transesophageal echocardiography and management
by experienced cardiac anesthesiologists. The single episode
of pneumonia in our series may have been related to
single-lung ventilation and general anesthesia. However,
this patient had been hospitalized in heart failure and had
been treated for pneumonia preoperatively.
In summary, robotically assisted LV epicardial lead im-
plantation is a safe, reliable, fast, and effective technique for
ventricular resynchronization. Presently, it is an important
technique to allow for minimally invasive rescue in the
setting of failed CS cannulation. Given the success of
isolated LV pacing, this procedure could conceivably exist as
a simple, stand-alone technique with the addition of an
atrial lead. This would avoid the potential deleterious effects
of right ventricular pacing while maintaining the beneficial
effects of LV pacing. Prospective randomized studies will be
necessary to determine the role of robotic LV epicardial lead
implantation in primary ventricular resynchronization
therapy.
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